Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Covington
Accenture
Cantor Fitzgerald
Medtronic
Deloitte

Generated: April 26, 2019

DrugPatentWatch Database Preview

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION Drug Profile

« Back to Dashboard

Which patents cover Allegra-d 12 Hour Allergy And Congestion, and what generic alternatives are available?

Allegra-d 12 Hour Allergy And Congestion is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION is fexofenadine hydrochloride; pseudoephedrine hydrochloride. There are twenty-three drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the fexofenadine hydrochloride; pseudoephedrine hydrochloride profile page.

Drug patent expirations by year for ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
Pharmacology for ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
Synonyms for ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
616242-78-5
Allegra D
Allegra D 24 Hour
Allegra d-12 hour
ALLEGRA-D
Allegra-D 12 Hour
Allegra-D 24 Hour Allergy and Congestion
Benzeneacetic acid, 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1- piperidinyl)butyl)-alpha,alpha-dimethyl-, hydrochloride, mixt. with (alphaS)-alpha-((1S)-1-(methylamino)ethyl)benzenemethanol hydrochloride
fenadine HCl + Pseudoephedrine HCl
Fexofenadine HCl; pseudoephedrine HCl
Fexofenadine hydrochloride and pseudoephedrine hydrochloride
Fexofenadine hydrochloride mixture with Pseudoephedrine hydrochloride
Fexofenadine mixture with pseudoephedrine

US Patents and Regulatory Information for ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION fexofenadine hydrochloride; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020786-002 Jan 24, 2011 OTC Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION fexofenadine hydrochloride; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020786-002 Jan 24, 2011 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION fexofenadine hydrochloride; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020786-002 Jan 24, 2011 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION fexofenadine hydrochloride; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020786-002 Jan 24, 2011 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION fexofenadine hydrochloride; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020786-002 Jan 24, 2011 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION fexofenadine hydrochloride; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020786-002 Jan 24, 2011 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION fexofenadine hydrochloride; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020786-002 Jan 24, 2011 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION fexofenadine hydrochloride; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020786-002 Jan 24, 2011 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Merck
Federal Trade Commission
Fuji
Julphar
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.